Case Reports in Dermatology最新文献

{"title":"Multiple Dermatomyofibromas in a Patient with Ehlers-Danlos Syndrome.","authors":"Mark Lewis Derbyshire,&nbsp;Amy Leigh Brady,&nbsp;Ramsay Sami Farah","doi":"10.1159/000530423","DOIUrl":"https://doi.org/10.1159/000530423","url":null,"abstract":"<p><p>Dermatomyofibromas are a rare, benign, acquired neoplasm with less than 150 reported cases worldwide. The etiologic factors that contribute to the development of these lesions are currently unknown. To our knowledge, there have been only six previously reported cases of patients presenting with multiple dermatomyofibromas, and in each of these cases, there were less than ten lesions present. Herein, we describe a patient who developed more than 100 dermatomyofibromas over a period of years, and we argue that the patient's concurrent Ehlers-Danlos syndrome could have contributed to this unique presentation by inducing an increased fibroblast-to-myofibroblast transition.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"15 1","pages":"1"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9714522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pool Toes: A Case Report.","authors":"Mohammad Munshi,&nbsp;Luca Borradori,&nbsp;Nikhil Yawalkar,&nbsp;Kristine Heidemeyer","doi":"10.1159/000529079","DOIUrl":"https://doi.org/10.1159/000529079","url":null,"abstract":"<p><p>Pool toes, a sport-related dermatosis, are caused by mechanical friction and water exposure, resulting in a special variant of irritant contact dermatitis. It is common in children, often misdiagnosed, and rarely reported. Here we report a case of a 7-year-old girl who developed this unusual type of frictional dermatitis; a pool toes diagnosis has been made. With topical corticosteroids, favorable results have been achieved. The recovery and healing process will be facilitated if one is aware of the underlying causes of such dermatitis and ceases the triggering factors.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"15 1","pages":"31-34"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10668876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report.","authors":"Angelo Ruggiero,&nbsp;Wanda Lauro,&nbsp;Chiara Miano,&nbsp;Alessia Villani,&nbsp;Gabriella Fabbrocini,&nbsp;Claudio Marasca","doi":"10.1159/000525347","DOIUrl":"https://doi.org/10.1159/000525347","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is an inflammatory skin disease showing a chronic-remitting course. It has been rarely reported that long-term inflammation in HS could lead to serious complications like cutaneous squamous cell carcinoma. Cemiplimab is a fully human antibody immunotherapy that inhibits programmed cell death protein-1, approved for the treatment of locally advanced squamous cell carcinoma, or metastatic squamous cell carcinoma, in patients not eligible for curative surgery or radiotherapy. Herein, we report the case of a 56-year-old patient developing an invasive SCC on longstanding and unresponsive HS lesions successfully treated with cemiplimab.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"15 1","pages":"35-39"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/c1/cde-2023-0015-0001-525347.PMC9929653.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients.","authors":"Kamran Balighi,&nbsp;Sama Heidari,&nbsp;Mohammadreza Kavyani,&nbsp;Kambiz Kamyab Hesari,&nbsp;Nasim Tootoonchi","doi":"10.1159/000527913","DOIUrl":"https://doi.org/10.1159/000527913","url":null,"abstract":"<p><p>Bullous pemphigoid is the most common acquired bullous disease with an autoimmune basis and a tendency to involve mostly old people. By rising incidence of diabetes all over the world, consumption of antidiabetes medications has also increased. One of the most used antidiabetes drugs is gliptin family (dipeptidyl-peptidase 4 inhibitor). Recently, this class of oral antidiabetic agents showed a correlation with the occurrence of bullous pemphigoid and its subtypes, including mucous membrane pemphigoid and pemphigoid nodularis. We are reporting a case series of 4 diabetes patients that we diagnosed with bullous pemphigoid subtypes (mucous membrane pemphigoid, pemphigoid nodularis, and its rarest subtype, linear IgA bullous dermatosis) after taking different drugs of gliptin family.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"350-355"},"PeriodicalIF":0.9,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/c5/cde-0014-0350.PMC9710457.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35344576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Chronic Venous Ulcer with Cold Atmospheric Plasma Jet.","authors":"Shirin Samsavar,&nbsp;Hamidreza Mahmoudi,&nbsp;Mohammad Reza Khani,&nbsp;Maryam Daneshpazhooh,&nbsp;Babak Shokri","doi":"10.1159/000527018","DOIUrl":"https://doi.org/10.1159/000527018","url":null,"abstract":"<p><p>Nowadays, cold atmospheric plasma jet (CAP-jet) shows interesting results in the dermatology sector, particularly focusing on wound healing and antimicrobial properties. The purpose of this case report is to present a nonthermal atmospheric pressure plasma treatment as a novel therapy for venous ulcers. The plasma consists of ionized helium gas that is produced by a high-voltage (4.5 kV) and high-frequency power supply (22 kHz). We here present a 65-year-old man with a slow-healing ulcer on the right lower limb. The CAP was applied to the ulcer twice a week for four consecutive weeks and the patient was followed for 6 weeks. The amount of exudate, ulcer size, and wound grading were determined weekly. The results showed that exudate from the ulcer significantly reduced in the first week after complete treatment, the wound grading of the ulcer improved by the second week, and the size of the ulcer significantly decreased after 2 weeks. The ulcer entirely healed after 4 weeks without any signs of infection. This case study demonstrates that applying CAP-jet can decrease the bacterial load on the ulcer site and stimulate tissue regeneration concurrently. This increases the speed of the healing process.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"344-349"},"PeriodicalIF":0.9,"publicationDate":"2022-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/69/cde-0014-0344.PMC9710460.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35253585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Acute Myeloid Leukemia-Associated Necrotizing Sweet Syndrome.","authors":"Jennifer Strong,&nbsp;Albert E Zhou,&nbsp;Fahad Alkaabba,&nbsp;Danielle Soldin,&nbsp;Joanne Moon,&nbsp;Hanan Alharthy,&nbsp;Owais Syed,&nbsp;Yuchen Liu,&nbsp;Kathryn Turney,&nbsp;Janina Markidan,&nbsp;Laura Malone,&nbsp;Seung Tae Lee,&nbsp;Peter DeRosa","doi":"10.1159/000527597","DOIUrl":"https://doi.org/10.1159/000527597","url":null,"abstract":"<p><p>Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is a rare painful skin condition that is characterized by hyperpyrexia, peripheral blood and skin neutrophilia, and edematous skin lesions. Necrotizing SS (NSS) is a severe and locally aggressive condition that histopathologically resembles a necrotizing soft tissue infection. As opposed to necrotizing soft tissue infections, NSS responds to systemic steroids. SS is divided into three subtypes: classical SS, malignancy-associated SS, and drug-induced SS. Within the malignancy-associated SS subtype, both solid tumor and hematologic malignancies have been precursors to developing SS. Here, we present a case of acute myeloid leukemia-associated NSS.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"339-343"},"PeriodicalIF":0.9,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/a7/cde-0014-0339.PMC9710466.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35344573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report.","authors":"Martina Burlando,&nbsp;Ilaria Salvi,&nbsp;Andrea Paravisi,&nbsp;Emanuele Cozzani,&nbsp;Aurora Parodi","doi":"10.1159/000526037","DOIUrl":"https://doi.org/10.1159/000526037","url":null,"abstract":"<p><p>Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"326-329"},"PeriodicalIF":0.9,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/9c/cde-0014-0326.PMC9710421.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35257010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous Panniculitis-like T-Cell Lymphoma with a Transformation to Lupus Erythematosus Panniculitis: A Case Report.","authors":"Weeratian Tawanwongsri,&nbsp;Jirapan Thongsroy","doi":"10.1159/000527530","DOIUrl":"https://doi.org/10.1159/000527530","url":null,"abstract":"<p><p>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare primary cutaneous lymphoma characterized by infiltration of the subcutaneous tissue by neoplastic cytotoxic T cells mimicking panniculitis. There is a strong association between SPTCL and lupus erythematosus panniculitis (LEP). However, patients who were diagnosed with LEP with a preceding diagnosis of SPTCL have been scarcely reported. We herein reported a 21-year-old Thai woman presenting to a dermatology clinic for evaluation of a 1-month history of a painful mass on the right buttock and bilateral upper eyelid swelling. A subcutaneous mass which was 5 by 2 cm in diameter, tender, firm, and fixed with a smooth surface was palpated over the upper outer quadrant of her right gluteal area. After a diagnosis of SPTCL had been made based on the histological and immunohistochemical studies, treatment with oral dexamethasone and ciclosporin A was initially started. Because of intolerance to adverse reactions of dexamethasone, only ciclosporin A was given. Improvement was not achieved at 6-month follow-up. She then underwent the re-incisional biopsy at the same gluteal area and the histological features were consistent with LEP. After hydroxychloroquine was given, the lesion resolved within 3 months, and no recurrence was detected during the following 6-month follow-up. We emphasize that long-term follow-up of patients with SPTCL is required. Additionally, in case of poor response to the given treatment, a repeat skin biopsy should be considered in order to determine the proper management.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"319-325"},"PeriodicalIF":0.9,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/87/cde-0014-0319.PMC9710456.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35344578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcium Electroporation for Management of Cutaneous Metastases in HER2-Positive Breast Cancer: A Case Report.","authors":"Katrine Borres Jensen,&nbsp;Camilla Kjaer Lonkvist,&nbsp;Julie Gehl,&nbsp;Mille Vissing","doi":"10.1159/000526157","DOIUrl":"https://doi.org/10.1159/000526157","url":null,"abstract":"<p><p>We report a case of successful treatment of cutaneous metastases in HER2-positive breast cancer with calcium electroporation (CaEP), in addition to trastuzumab, over a period of 5 years. CaEP is performed in local or general anesthesia, by injecting calcium chloride intratumorally and then electroporating cells in the area. Using a handheld needle electrode, a series of short, high-voltage electric pulses are delivered, which transiently permeabilizes cell membranes, causing toxic intracellular calcium levels. The treatment causes cancer cell death, while normal cells are less affected, making the treatment useful for local management of cutaneous lesions. This case presents a 66-year-old female, who had mastectomy surgery followed by adjuvant chemo- and radiotherapy for an ER-negative, HER2-positive breast cancer on her right side in 2003, and a mastectomy followed by endocrine therapy for an ER-positive, HER2 normal breast cancer on her left side in 2006. In 2015, the patient presented local cutaneous recurrence of the ER-negative, HER2-positive breast cancer. The patient was treated with trastuzumab alone, trastuzumab emtansine (TDM1), and a combination of trastuzumab and CaEP. TDM1 was found to have a slightly better effect on the cutaneous metastases than trastuzumab, but the side effects of TDM1 were not acceptable to the patient. The combination of continuous HER2-inhibition and intermittent CaEP, when needed, has been effective in keeping the cutaneous metastases under control for 5 years, and presumably more tolerable for the patient than chemotherapy. An interesting finding was local sparing of calcium electroporated skin from new recurrences, otherwise seen in the general area, which could be a sign of local immunity. This warrants further studies investigating local immunomodulation following CaEP. The patient reported appreciation of a treatment option without chemotherapy, and satisfaction with the outcome of the combination of HER2 inhibition and CaEP treatment. CaEP treatment is currently phase II treatment, and mechanisms and possible applications still need investigation. This novel anticancer treatment could potentially benefit many patients, due to its efficacy, low cost, and accessibility. This case provides observations, which may inspire future trials with CaEP for skin metastases of HER2-positive breast cancer.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"330-338"},"PeriodicalIF":0.9,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/74/cde-0014-0330.PMC9710443.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35253586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Unusual Presentation of Merkel Cell Carcinoma in the Setting of Immunosuppression on TNF-Alpha Inhibitor Therapy.","authors":"Kristen Delans, Rachel Semus, Nasiffa Hossain, Jack Ledford","doi":"10.1159/000527329","DOIUrl":"10.1159/000527329","url":null,"abstract":"<p><p>Merkel cell carcinoma (MCC) is a rare but deadly skin cancer, observed classically in the sun-damaged skin of older, white males. The cancer is characterized by rapid growth as well as high morbidity and mortality. In this article, we detail an atypical presentation of MCC in an African-American patient being treated with prednisone, methotrexate, and adalimumab for rheumatoid arthritis. Initially presenting as a subcutaneous nodule, the tumor in our patient was misdiagnosed first as an abscess and treated accordingly. Only after the subcutaneous mass failed to resolve with antibiotics as well as repeated incision and drainage was a biopsy performed, which yielded the final diagnosis. In the text, we detail the patient's symptomatology as well as steps that eventually lead to diagnostic confirmation. Our case demonstrates the importance of heightened clinical suspicion for MCC in immunosuppressed patients with unexplained subcutaneous nodules. Prompt diagnosis is crucial for positive outcomes; therefore, we aim to provide information that may aid in identification of MCC tumors in future patients. With the increasing use of biologic agents such as adalimumab to treat rheumatic disease, the literature is demonstrating an increasing incidence of previously \"rare\" malignancies such as MCC. It is crucial for physicians to convey these risks when initiating a patient on chronic immunosuppressive therapy and to provide routine surveillance for MCC and other complications.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"313-318"},"PeriodicalIF":0.9,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/f0/cde-0014-0313.PMC9710431.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35344579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}